NeoGenomics (NEO) director exercises 23,077 RSUs and receives new option, RSU grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NEOGENOMICS INC director Stephen M. Kanovsky reported equity compensation activity involving company stock. He exercised previously granted restricted stock units into 23,077 shares of Common Stock at $0.00 per share, bringing his direct Common Stock holdings to 75,421 shares. The filing notes this reflects the release of restricted stock units that were previously reported, and that once vested, the resulting shares are not subject to expiration.
Kanovsky also received new equity awards: 15,970 restricted stock units tied to Common Stock and a stock option for 11,069 shares of Common Stock with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. He continues to hold multiple existing stock option grants with exercise prices ranging from $7.28 to $40.90 per share and expiration dates from 2026 through 2035, providing additional potential future share exposure.
Positive
- None.
Negative
- None.
Insider Trade Summary
23,077 shares exercised/converted
Mixed
11 txns
Insider
KANOVSKY STEPHEN M
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 23,077 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | -- |
| Exercise | Common Stock | 23,077 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct, null);
Stock Option (Right to Buy) — 11,069 shares (Direct, null);
Common Stock — 75,421 shares (Direct, null)
Footnotes (1)
- Reflects the release of restricted stock units that were previously reported on a Form 4. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSUs exercised into common stock: 23,077 shares at $0.00
Common shares held after transaction: 75,421 shares
New RSU grant: 15,970 units
+3 more
6 metrics
RSUs exercised into common stock
23,077 shares at $0.00
Restricted stock units converted to Common Stock on June 1, 2026
Common shares held after transaction
75,421 shares
Direct NeoGenomics Common Stock holdings following RSU conversion
New RSU grant
15,970 units
Restricted Stock Units granted on June 1, 2026, vesting June 1, 2027
New stock option grant
11,069 shares at $10.52
Stock Option (Right to Buy) granted, exercisable June 1, 2027, expiring 2036-06-01
Remaining option at $7.28
16,107 underlying shares
Stock option exercisable at $7.28, expiring 2035-06-01
Remaining option at $40.90
3,714 underlying shares
Stock option exercisable at $40.90, expiring 2028-06-02
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy), derivative security, grant, award, or other acquisition, +1 more
5 terms
Restricted Stock Unit financial
"Restricted Stock Unit transaction of 15,970.0000 underlying Common Stock shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with exercise prices such as 10.5200 per share"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price values like 7.2800 and 40.9000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transactions did NEO director Stephen Kanovsky report on this Form 4?
Stephen Kanovsky reported equity compensation activity, including exercising restricted stock units into 23,077 shares of Common Stock and receiving new awards of 15,970 restricted stock units and a stock option for 11,069 shares tied to NeoGenomics common stock.
What new equity awards did Stephen Kanovsky receive from NeoGenomics (NEO)?
Stephen Kanovsky received 15,970 restricted stock units and a stock option covering 11,069 shares of NeoGenomics Common Stock. The option has an exercise price of $10.52 per share, and both awards are scheduled to vest or become exercisable on June 1, 2027.
What stock options does Stephen Kanovsky still hold in NeoGenomics (NEO)?
Stephen Kanovsky holds several stock option grants on NeoGenomics Common Stock with exercise prices from $7.28 to $40.90 per share. These options cover underlying share amounts ranging from 3,448 to 16,107 and expire between 2026 and 2035.